Scholarlink

Objective <p>Summarize the effectiveness and safety of Semaglutide for non-diabetic obese patients through umbrella analysis.</p> Methods <p>From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity. AMSTAR-2 assessed review quality, ROB scrutinized RCT quality, and RCTs were selected based on overlap. Random-effects meta-analysis synthesized data on weight, waist, BMI, ect.</p> Results <p>The study encompassed 7 reviews and 10 RCTs, revealing that semaglutide induced average weight loss 11.71 kg [−13.16, −10.26] in non-diabetic obese patients, a 12.79% reduction [−14.4, −11.18]. Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased. Semaglutide also reduced waist by 9.39 cm [−10, −8.79], BMI by 4.27 kg/m^2 [−4.78, −3.75], SBP by 4.78 mmHg [−5.63, −3.93], DBP by 2.56 mmHg [−3.96, −1.17], and lipids by 3.2 mmol/l [−5.65, −0.75]. FBG significantly dropped by 5.46 mmol/l [−8.99, −1.93], and SF-36 scores improved by 1.7 points [0.78, 2.63]. However, common adverse reactions included nausea [RR: 2.59], diarrhea [RR: 1.77], and constipation [RR: 2.07].</p> Conclusions <p>Semaglutide shows significant weight loss and health benefits in non-diabetic obesity. However, Recent studies show semaglutide can cause NAION and erectile dysfunction, beyond previously reported adverse reactions. Besides, High overlap in current research highlights a lack of RCTs. And there is a high degree of heterogeneity across included studies. More large-scale, rigorous RCTs are needed to assess safety and support clinical use.</p> Register <p>The study was registered at PROSPERO on 24 December 2023 (registration number:CRD42023493235).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews

  • 期刊论文

  • 发表日期：

    2025年2月16日

查看全文
  • Xiaoye Hu,
  • Yongsheng Wang,
  • Kehu Yang,
  • Xiuxia Li

摘要

Objective

Summarize the effectiveness and safety of Semaglutide for non-diabetic obese patients through umbrella analysis.

Methods

From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity. AMSTAR-2 assessed review quality, ROB scrutinized RCT quality, and RCTs were selected based on overlap. Random-effects meta-analysis synthesized data on weight, waist, BMI, ect.

Results

The study encompassed 7 reviews and 10 RCTs, revealing that semaglutide induced average weight loss 11.71 kg [−13.16, −10.26] in non-diabetic obese patients, a 12.79% reduction [−14.4, −11.18]. Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased. Semaglutide also reduced waist by 9.39 cm [−10, −8.79], BMI by 4.27 kg/m^2 [−4.78, −3.75], SBP by 4.78 mmHg [−5.63, −3.93], DBP by 2.56 mmHg [−3.96, −1.17], and lipids by 3.2 mmol/l [−5.65, −0.75]. FBG significantly dropped by 5.46 mmol/l [−8.99, −1.93], and SF-36 scores improved by 1.7 points [0.78, 2.63]. However, common adverse reactions included nausea [RR: 2.59], diarrhea [RR: 1.77], and constipation [RR: 2.07].

Conclusions

Semaglutide shows significant weight loss and health benefits in non-diabetic obesity. However, Recent studies show semaglutide can cause NAION and erectile dysfunction, beyond previously reported adverse reactions. Besides, High overlap in current research highlights a lack of RCTs. And there is a high degree of heterogeneity across included studies. More large-scale, rigorous RCTs are needed to assess safety and support clinical use.

Register

The study was registered at PROSPERO on 24 December 2023 (registration number:CRD42023493235).